Primary and secondary prevention of cervical cancer (based on the recommendations of the American Society of Clinical Oncology, march 2017)

Cover Page
  • Authors: Dubrovina S.O1,2
  • Affiliations:
    1. Rostov State Medical University of the Ministry of Health of the Russian Federation
    2. Rostov Research Institute of Obstetrics and Pediatrics of the Ministry of Health of the Russian Federation
  • Issue: Vol 19, No 6 (2017)
  • Pages: 66-71
  • Section: Articles
  • URL: https://journals.rcsi.science/2075-1753/article/view/94803
  • ID: 94803

Cite item

Full Text

Abstract

The article outlines the main provisions of the recommendations of the American Society of Clinical Oncology for primary and secondary prevention of cervical cancer by vaccination and screening programs.

About the authors

S. O Dubrovina

Rostov State Medical University of the Ministry of Health of the Russian Federation; Rostov Research Institute of Obstetrics and Pediatrics of the Ministry of Health of the Russian Federation

Email: s.dubrovina@gmail.com
д-р мед. наук, проф., проф. каф. акушерства и гинекологии №1 ФГБОУ ВО РостГМУ, гл. науч. сотр. ФГБУ РНИИАП 344022, Russian Federation, Rostov-on-Don, per. Nakhichevanskii, d. 29; 344012, Russian Federation, Rostov-on-Don, ul. Mechnikova, d. 43

References

  1. De Sanjosé S, Temin S, Garland S et al. Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource - Stratified Guideline Summary. J Oncol Pract 2017; 25: JOP2017021949. doi: 10.1200/JOP.2017.021949.
  2. Forman D, de Martel C, Lacey C.J et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 (Suppl. 5): F12-23. doi: 10.1016/j.vaccine.2012.07.055.
  3. Castellsagué X, Alemany L, Quer M et al. HPV involvement in head and neck cancers: Comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst 108:djv403, 2016 HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. J Nat l Cancer Inst 2016; 108 (6): djv403. doi: 10.1093/jnci/djv403.
  4. De Sanjosé S, Serrano B, Castellsagué X et al. Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report. Vaccine 2012; 30 (Suppl. 4): D1-83, vi. doi: 10.1016/S0264-410X(12)01435-1.
  5. De Sanjosé S, Wheeler C.M, Quint W.G et al. Age - specific occurrence of HPV16- and HPV18-related cervical cancer.Cancer Epidemiol Biomarkers Prev 2013; 22 (7): 1313-8. doi: 10.1158/1055-9965.EPI-13-0053.
  6. De Sanjosé S1, Quint W.G, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross - sectional worldwide study. Lancet Oncol 2010; 11 (11): 1048-56. doi: 10.1016/S1470-2045(10)70230-8. Epub 2010 Oct 15.
  7. Wheeler C.M, Castellsagué X, Garland S.M et al. Cross - protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non - vaccine oncogenic HPV types: 4-year end - of - study analysis of the randomised, double - blind PATRICIA trial. Lancet Oncol 2012; 13 (1): 100-10. doi: 10.1016/S1470-2045(11)70287-X. Epub 2011 Nov 8.
  8. Schiller J.T, Castellsagué X, Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 (Suppl. 5): F123-38. doi: 10.1016/j.vaccine.2012.04.108.
  9. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014; 89 (43): 465-91.
  10. Couto E, Sæterdal I, Juvet L.K, Klemp M. HPV catch - up vaccination of young women: a systematic review and meta - analysis. BMC Public Health 2014; 14: 867. doi: 10.1186/1471-2458-14-867.
  11. Public Health Agency of Canada National Advisory Committee on Immunization: Update on the recommendedhu man papillomavirus (HPV) vaccine immunization schedule. https://www.canada.ca/en/public-health/services/publications/healthy-living/update recommended-human-papillomavirus-vaccine-immunization-schedule.html
  12. Vichnin M, Bonanni P, Klein N.P et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J 2015; 34 (9): 983-91. doi: 10.1097/INF.0000000000000793.
  13. Garland S.M, Ault K.A, Gall S.A et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009; 114 (6): 1179-88. doi: 10.1097/AOG.0b013e3181c2ca21.
  14. Brotherton J.M. Safety of the quadrivalent human papillomavirus vaccine. BMJ 2013; 347: f5631. doi: 10.1136/bmj.f5631.
  15. Arnheim-Dahlström L, Pasternak B, Svanström H et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013; 347: f5906. doi: 10.1136/bmj.f5906.
  16. Global Advisory Committee on Vaccine Safety, 2-3 December 2015. Wkly Epidemiol Rec 2016; 91 (3): 21-31.
  17. Markowitz L.E, Dunne E.F, Saraiya M et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56 (RR-2): 1-24.
  18. Chuang L.T, Temin S, Berek J.S. Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource - Stratified Clinical Practice Guideline Summary. J Oncol Pract 2016; 12 (7): 693-6. doi: 10.1200/JOP.2016.014290. Epub 2016 Jun 21.
  19. Jeronimo J, Castle PE, Temin S, Shastri S.S. Secondary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. J Oncol Pract 2017; 13 (2): 129-33. doi: 10.1200/JOP.2016.017889. Epub 2016 Nov 15.
  20. Massad L.S, Einstein M.H, Huh W.K et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013; 121 (4): 829-46. doi: 10.1097/AOG.0b013e3182883a34.
  21. World Health Organization: WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention: WHO Guidelines Approved by the Guidelines Review Committee. Geneva, Switzerland, World Health Organization, 2013.
  22. Arnheim-Dahlström L, Pasternak B, Svanström H et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013; 347: f5906. doi: 10.1136/bmj.f5906.
  23. Markowitz L.E, Dunne E.F, Saraiya M et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63 (RR-05): 1-30.
  24. European Medicines Agency: HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS http://www.ema.europa.eu/ema/index. jspcurl5pages/medicines/ human/referrals/Human_papillomavirus _vaccines/ human_referral_prac_ 000053.jsp&mid5 WC0b01ac05805c516f
  25. Centers for Disease Control and Prevention, Food and Drug Administration: Vaccine Adverse Event Reporting System (VAERS). https://vaers.hhs.gov/index
  26. Garland S.M, Stanley M, Brotherton J et al. IPVS policy statement on safety of HPV vaccines. Papillomavirus Res 2: 9-10, 2016.
  27. Meites E, Kempe A, Markowitz L.E. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. Am J Transplant 2017; 17 (3): 834-7. doi: 10.1111/ajt.14206.
  28. Garland S.M, Subasinghe A.K, Jayasinghe Y.L et al. HPV vaccination for victims of childhood sexual abuse. Lancet 2015; 386 (10007): 1919-20. doi: 10.1016/S0140-6736(15)00757-6. Epub 2015 Nov 13.
  29. Bailey H.H, Chuang L.T, du Pont N.C et al. American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. J Clin Oncol 2016; 34 (15): 1803-12. doi: 10.1200/JCO.2016.67.2014. Epub 2016 Apr 11.
  30. Dorell C, Yankey D, Kennedy A, Stokley S. Factors that influence parental vaccination decisions for adolescents, 13 to 17 years old: National Immunization Survey - Teen, 2010. Clin Pediatr (Phila) 2013; 52 (2): 162-70. doi: 10.1177/0009922812468208. Epub 2012 Dec 6.
  31. Gerend M.A, Madkins K, Phillips G, Mustanski B. Predictors of Human Papillomavirus Vaccination Among Young Men Who Have Sex With Men. Sex Transm Dis 2016; 43 (3): 185-91. doi: 10.1097/OLQ.0000000000000408.
  32. Gerend M.A, Shepherd M.A, Lustria M.L, Shepherd J.E. Predictors of provider recommendation for HPV vaccine among young adult men and women: findings from a cross - sectional survey. Sex Transm Infect 2016; 92 (2): 104-7. doi: 10.1136/sextrans-2015-052088. Epub 2015 Aug 21.
  33. Rosenthal S.L, Weiss T.W, Zimet G.D et al. Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation. Vaccine 2011; 29 (5): 890-5. doi: 10.1016/j.vaccine.2009.12.063. Epub 2010 Jan 5.
  34. Lee Mortensen G, Adam M, Idtaleb L. Parental attitudes towards male human papillomavirus vaccination: a pan - European cross - sectional survey. BMC Public Health 2015; 15: 624. doi: 10.1186/s12889-015-1863-6.
  35. Campos N.G, Tsu V, Jeronimo J et al: When and how often to screen for cervical cancer in three low - and middle - income countries: A cost - effectiveness analysis. Papillomavirus Res 2015; 1: 38-58.
  36. National Cancer Institute: Cervical Cancer Screening-Health Professional Version (PDQ®). Bethesda, MD, National Cancer Institute, 2016.
  37. Darragh T.M, Colgan T.J, Thomas Cox J et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013; 32 (1): 76-115. doi: 10.1097/PGP.0b013e31826916c7.
  38. Moyer V.A. U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 156 (12): 880-91, W312. doi: 10.7326/0003-4819-156-12-201206190-00424.
  39. Ikenberg H, Bergeron C, Schmidt D et al. Screening for cervical cancer precursors with p16/Ki-67 dual - stained cytology: results of the PALMS study. J Natl Cancer Inst 2013; 105 (20): 1550-7. doi: 10.1093/jnci/djt235. Epub 2013 Oct 4.
  40. Qiao Y.L, Jeronimo J, Zhao F.H et al. Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer 2014; 134 (12): 2891-901. doi: 10.1002/ijc.28616. Epub 2013 Dec 3.
  41. Mirabello L, Sun C, Ghosh A et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst 2012; 104 (7): 556-65. doi: 10.1093/jnci/djs135. Epub 2012 Mar 23.
  42. Wentzensen N, Sun C, Ghosh A et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012; 104 (22): 1738-49. doi: 10.1093/jnci/djs425. Epub 2012 Oct 23.
  43. Wentzensen N, Nason M, Schiffman M et al. No evidence for synergy between human papillomavirus genotypes for the risk of high - grade squamous intraepithelial lesions in a large population - based study. J Infect Dis 2014; 209 (6): 855-64. doi: 10.1093/infdis/jit577. Epub 2013 Oct 31.
  44. Joste N.E, Ronnett B.M, Hunt W.C et al. Human papillomavirus genotype - specific prevalence across the continuum of cervical neoplasia and cancer. Cancer Epidemiol Biomarkers Prev 2015; 24 (1): 230-40. doi: 10.1158/1055-9965.EPI-14-0775. Epub 2014 Nov 2.
  45. Kinde I, Bettegowda C, Wang Y et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013; 5 (167): 167ra4. doi: 10.1126/scitranslmed.3004952.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies